Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
Brigham and Women's Hospital
Summary
This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.
Eligibility
- Age range
- 21–80 years
- Sex
- All
- Healthy volunteers
- No
A. Inclusion Criteria: * Age 21 years to 80 years (inclusive) * eGFR of 15 to 75 mL/min per 1.73 m2 * Urine albumin-to-creatinine ratio of greater than 30 mg/g * Use of maximally tolerated doses of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker if urine albumin-to-creatinine ratio greater than 300 mg-g * Use of a sodium-glucose co-transporter-2 inhibitor if indicated in the opinion of the participant's primary clinician * Willing and able to provide written informed consent and to adhere to the study protocol B. Exclusion Criteria: 1. History of intolerance or al…
Interventions
- DrugColchicine
Colchicine
- DrugPlacebo
Placebo
Location
- Brigham and Women's HospitalBoston, Massachusetts